Rivaroxaban Dosing for Post-Operative DVT Treatment

Initial Treatment Phase

The American College of Cardiology recommends administering rivaroxaban 15 mg twice daily with food for the first 21 days to provide strong anticoagulation when thrombus burden is highest 1
Food intake significantly improves drug absorption and ensures adequate anticoagulation during the acute phase 1
No parenteral anticoagulation is required before starting rivaroxaban, making it a convenient single-drug regimen 1

For low bleeding risk surgery, resume rivaroxaban 24 hours post-operatively at full treatment dose (15 mg twice daily) once hemostasis is assured 2, 3, 4, 5
For high bleeding risk surgery, resume rivaroxaban 48-72 hours post-operatively (2-3 days after surgery) 2, 3, 4, 5
For patients at high thromboembolism risk, consider starting with a reduced dose of 10 mg once daily for the first 2-3 days, then transition to the standard 15 mg twice daily regimen 3, 4, 5

Prophylactic-dose LMWH or fondaparinux can be initiated 6-12 hours post-operatively if VTE prophylaxis is indicated while waiting to start therapeutic rivaroxaban 6, 7
When transitioning from prophylactic LMWH to therapeutic rivaroxaban, administer the first rivaroxaban dose 12 hours after the last prophylactic LMWH dose 7
No therapeutic-dose heparin bridging is needed except in very high thrombotic risk patients 7

Transition to rivaroxaban 20 mg once daily with food after completing the 21-day initial phase 1
Continue for a minimum of 3 months, with total duration determined by underlying VTE risk factors 1
For extended secondary prevention beyond 6 months, consider reducing to 10 mg once daily 1

No dose adjustment is needed for creatinine clearance 30-49 mL/min during DVT treatment 1
Avoid rivaroxaban in severe renal failure (CrCl <15 mL/min) 1
Monitor renal function post-operatively as surgical procedures may affect kidney function 7
Use the same standard dosing regimen (15 mg twice daily × 21 days, then 20 mg once daily) for cancer patients 1
Rivaroxaban demonstrates similar efficacy with potentially lower major bleeding rates (2% vs 5%) compared to standard therapy in cancer patients 1
Do not initiate therapeutic-dose rivaroxaban while an epidural catheter is in place 7
Use prophylactic-dose heparin instead, which allows safe catheter management 7
Only transition to therapeutic rivaroxaban after catheter removal 7

Never start with 20 mg once daily from day 1 - this provides inadequate anticoagulation during the acute phase when thrombus burden is highest 2, 3, 5
Do not resume therapeutic anticoagulation too early post-operatively - this significantly increases bleeding risk, particularly in major surgery 2, 3, 5
Always administer with food - rivaroxaban absorption is significantly reduced without food, potentially leading to treatment failure 1
Avoid in patients with neuraxial anesthesia/epidural catheters until catheter removal to prevent spinal/epidural hematoma 7

No routine coagulation monitoring is required unlike warfarin 1
Baseline labs: CBC, renal and hepatic function, aPTT, PT/INR 1
Follow-up: Hemoglobin, hematocrit, platelets every 2-3 days for first 14 days, then every 2 weeks 1

For patients with DVT provoked solely by surgery, 3 months of treatment is sufficient, according to the Mayo Clinic Proceedings, in patients with low-to-moderate bleeding risk 8, 9
Extended therapy beyond 3 months is recommended for patients at low-to-moderate bleeding risk with unprovoked or mixed risk DVT, as stated by the Mayo Clinic Proceedings 8, 9

Treatment may be discontinued after 3 months in patients with high bleeding risk, as suggested by the Mayo Clinic Proceedings 8